Cancer and Leukemia Group B trials for advanced prostate cancer.
The approach to treatment for advanced prostate cancer patients who have failed to respond to therapy with androgen deprivation has undergone a significant and fundamental transformation over the last 3 years, beginning with the description of the flutamide-withdrawal syndrome in 1993. This was the same year that the Cancer and Leukemia Group B Prostate Cancer Committee was created. This committee has been studying the following two important areas in advanced prostate cancer the optimal treatment and biology of androgen-independent, yet hormonally sensitive, prostate cancer; and the optimal treatment for patients with truly hormone-refractory disease. Important biologic and quality of life correlative trials will complement the clinical information gained, with the goal of providing further insight into the extremely complex biological processes involved.
Small
E J
EJ
University of California, San Francisco, School of Medicine, USA.
Dawson
N A
NA
Kantoff
P W
PW
Vogelzang
N J
NJ
D002986:Clinical Trials as Topic; D006801:Humans; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy* / Q000473:pathology; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011788:Quality of Life